GSK plc has announced an agreement to acquire 35Pharma Inc., a Canada-based, private, clinical-stage biopharmaceutical company.
The deal brings HS235, a potential best-in-class investigational therapy, into GSK’s pipeline.
Pulmonary hypertension is a progressive, life-shortening disease. Despite its scale, treatment options remain limited.
Key facts shaping the opportunity:
This acquisition directly targets that gap.
HS235 has completed Phase I healthy volunteer trials. Studies in patients are set to begin imminently.
Initial focus indications include:
HS235 targets the activin receptor signalling pathway, a validated mechanism in PH.
Existing therapies often interfere with BMP9 and BMP10. That interaction is linked to bleeding and vascular side effects.
HS235 is engineered for enhanced selectivity, aiming to:
This could address a major limitation in current PH care.
Early clinical data suggest broader metabolic benefits.
Observed effects include:
These benefits are particularly relevant given obesity and insulin resistance in PH patients.
Tony Wood, Chief Scientific Officer at GSK, highlighted HS235’s differentiated profile. The asset supports GSK’s ambition across:
This opens development opportunities beyond lung disease.
According to CEO Ilia Tikhomirov, advances in PH biology have reshaped treatment possibilities. Partnering with GSK accelerates HS235’s potential to transform care for a debilitating condition.
PH is treated in specialised academic centres. Care sits at the intersection of pulmonology and cardiology. In the US alone:
HS235 positions GSK to compete meaningfully in this underserved market.
Bottom line: GSK is buying more than an asset. It is buying optionality across pulmonary, metabolic, and inflammatory disease pathways.